Phase 1b/2, Multicenter, Open-label Study of the Safety and Activity of ONYX 0912 in Patients with Hematological Malignancies
ID Number 12-1673
Principal Investigator(s)Sundar Jagannath
Department(s) or Division(s)
Hematology and Medical Oncology
Description
The purpose of this study is to test the safety of an investigational new drug (a drug that has not received approval by the Food and Drug Administration [FDA]) called oprozomib at different dose levels. We want to find out what effects, good and/or bad, it has on you and your cancer.
Oprozomib, is an investigational drug that has been previously tested in approximately 48 subjects and has also been studied in animals.
Oprozomib works by preventing breakdown of proteins in cells, causing the cells to die. Cancer cells are more susceptible to these effects than normal cells.
Oprozomib is a drug that comes in the form of a tablet. Depending on the dose you will take, you may need to take several tablets. You will take all the tablets making up your dose by mouth at the same time. Your dose may be decreased during the study as information is learned about the safety of the dose you are on and the safety of higher doses. Your dose may also be decreased based upon your response to therapy.
Contact Information
Lisa La
(212) 241-8615
Recruiting Patients: Yes